-
EP3160473
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3160473
| EP3160473 - BRIMONIDINE FOR USE IN A METHOD OF TREATING HAND-FOOT SYNDROME AND SYMPTOMS ASSOCIATED THEREWITH [Right-click to bookmark this link] | |||
| Former [2017/18] | METHOD OF TREATING HAND-FOOT SYNDROME AND SYMPTOMS ASSOCIATED THEREWITH | ||
| [2023/19] | Status | The application is deemed to be withdrawn Status updated on 02.02.2024 Database last updated on 07.06.2024 | |
| Former | Grant of patent is intended Status updated on 11.05.2023 | ||
| Former | Examination is in progress Status updated on 24.11.2017 | ||
| Former | Request for examination was made Status updated on 31.03.2017 | ||
| Former | The international publication has been made Status updated on 11.01.2017 | Most recent event Tooltip | 02.02.2024 | Application deemed to be withdrawn | published on 06.03.2024 [2024/10] | Applicant(s) | For all designated states Galderma S.A. World Trade Center Avenue Gratta-Paille 1 1000 Lausanne 30 Grey / CH | [2017/18] | Inventor(s) | 01 /
ANDRES, Philippe 126 Avenue des Termes 06530 Peymeinade / FR | [2017/18] | Representative(s) | V.O. P.O. Box 87930 Carnegieplein 5 2508 DH Den Haag / NL | [2017/18] | Application number, filing date | 15730502.0 | 22.06.2015 | [2017/18] | WO2015EP63930 | Priority number, date | US201462016324P | 24.06.2014 Original published format: US 201462016324 P | [2017/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015197524 | Date: | 30.12.2015 | Language: | EN | [2015/52] | Type: | A1 Application with search report | No.: | EP3160473 | Date: | 03.05.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.12.2015 takes the place of the publication of the European patent application. | [2017/18] | Search report(s) | International search report - published on: | EP | 30.12.2015 | Classification | IPC: | A61K31/498, A61P17/00 | [2017/18] | CPC: |
A61K31/498 (EP,CN,KR,US);
A61K45/00 (CN);
A61K31/131 (US);
A61K31/137 (US);
A61K31/4164 (US);
A61K47/14 (CN);
A61K9/0014 (CN,US);
A61K9/06 (CN,KR);
A61P17/00 (EP);
A61P17/02 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/18] | Title | German: | BRIMONIDINE ZUR VERWENDUNG IN EINER METHODE ZUR BEHANDLUNG DES HAND-FUSS-SYNDROMS UND ASSOZIIERTER SYMPTOME | [2023/19] | English: | BRIMONIDINE FOR USE IN A METHOD OF TREATING HAND-FOOT SYNDROME AND SYMPTOMS ASSOCIATED THEREWITH | [2023/19] | French: | BRIMONIDINE POUR SON UTILISATION DANS UNE MÉTHODE POUR LE TRAITEMENT DU SYNDROME D'ENFLURE DOULOUREUSE DES MAINS ET DES PIEDS ET DES SYMPTOMES ASSOCIÉS | [2023/19] |
| Former [2017/18] | VERFAHREN ZUR BEHANDLUNG DES HAND-FUSS-SYNDROMS UND DAMIT ASSOZIIERTEN SYMPTOME | ||
| Former [2017/18] | METHOD OF TREATING HAND-FOOT SYNDROME AND SYMPTOMS ASSOCIATED THEREWITH | ||
| Former [2017/18] | MÉTHODE DE TRAITEMENT DU SYNDROME MAIN-PIED ET DES SYMPTÔMES ASSOCIÉS | Entry into regional phase | 11.01.2017 | National basic fee paid | 11.01.2017 | Designation fee(s) paid | 11.01.2017 | Examination fee paid | Examination procedure | 11.01.2017 | Amendment by applicant (claims and/or description) | 11.01.2017 | Examination requested [2017/18] | 11.01.2017 | Date on which the examining division has become responsible | 23.11.2017 | Despatch of a communication from the examining division (Time limit: M04) | 08.03.2018 | Reply to a communication from the examining division | 22.11.2018 | Despatch of a communication from the examining division (Time limit: M04) | 27.03.2019 | Reply to a communication from the examining division | 02.09.2019 | Despatch of a communication from the examining division (Time limit: M06) | 24.02.2020 | Reply to a communication from the examining division | 12.01.2021 | Despatch of a communication from the examining division (Time limit: M04) | 21.05.2021 | Reply to a communication from the examining division | 29.06.2022 | Despatch of a communication from the examining division (Time limit: M04) | 26.10.2022 | Reply to a communication from the examining division | 12.05.2023 | Communication of intention to grant the patent | 23.09.2023 | Application deemed to be withdrawn, date of legal effect [2024/10] | 18.10.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2024/10] | Fees paid | Renewal fee | 16.06.2017 | Renewal fee patent year 03 | 12.06.2018 | Renewal fee patent year 04 | 13.06.2019 | Renewal fee patent year 05 | 31.03.2020 | Renewal fee patent year 06 | 14.06.2021 | Renewal fee patent year 07 | 27.06.2022 | Renewal fee patent year 08 | 31.03.2023 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y] - M Tian ET AL, "Photobiology | ABSTRACTS 1251 The alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB-induced sunburn model", Journal of investigative dermatology, (20130501), page S213, URL: http://www.nature.com/jid/journal/v133/n1s/pdf/jid2013104a.pdf, (20140724), XP055131572 [Y] 1-21 * abstract 1251 * | [Y] - MACEDO LÍGIA TRALDI ET AL, "Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials", SUPPORTIVE CARE IN CANCER, SPRINGER VERLAG, BERLIN, DE, vol. 22, no. 6, doi:10.1007/S00520-014-2129-Z, ISSN 0941-4355, (20140126), pages 1585 - 1593, (20140126), XP035316115 [Y] 1-21 * paragraph bridging pages 1588-1589 * DOI: http://dx.doi.org/10.1007/s00520-014-2129-z | [A] - D PIWNICA ET AL, "Vasoconstriction and anti-inflammatory properties of the alpha adrenergic receptor agonist brimonidine", INTERNATIONAL INVESTIGATIVE DERMATOLOGY MEETING; EDINBURGH, UK, (20130508), page S23, XP055207736 [A] 1-21 * abstract 138 * |